Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
Status:
Recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies whether atezolizumab in combination with talazoparib works better
than atezolizumab alone as maintenance therapy for patients with SLFN11-positive
extensive-stage small cell lung cancer. Immunotherapy with monoclonal antibodies, such as
atezolizumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. PARPs are proteins that help repair damage to DNA,
the genetic material that serves as the body's instruction book. Changes (mutations) in DNA
can cause tumor cells to grow quickly and out of control, but PARP inhibitors like
talazoparib may keep PARP from working, so tumor cells can't repair themselves, and they stop
growing. Giving atezolizumab in combination with talazoparib may help lower the chance of
extensive-stage small cell lung cancer growing and spreading compared to atezolizumab alone.